Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
42.86
Dollar change
-0.05
Percentage change
-0.12
%
Index- P/E- EPS (ttm)-2.51 Insider Own14.69% Shs Outstand46.41M Perf Week-2.32%
Market Cap1.99B Forward P/E- EPS next Y-0.93 Insider Trans0.00% Shs Float39.59M Perf Month-0.95%
Income-89.51M PEG- EPS next Q-0.21 Inst Own81.44% Short Float8.19% Perf Quarter18.07%
Sales0.00M P/S- EPS this Y-15.82% Inst Trans- Short Ratio5.12 Perf Half Y20.06%
Book/sh9.76 P/B4.39 EPS next Y0.55% ROA-30.87% Short Interest3.24M Perf Year102.07%
Cash/sh10.07 P/C4.26 EPS next 5Y- ROE-33.29% 52W Range21.21 - 75.02 Perf YTD5.15%
Dividend Est.- P/FCF- EPS past 5Y- ROI-19.59% 52W High-42.87% Beta-5.12
Dividend TTM- Quick Ratio19.14 Sales past 5Y0.00% Gross Margin- 52W Low102.07% ATR (14)2.71
Dividend Ex-Date- Current Ratio19.14 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)56.63 Volatility5.53% 6.98%
Employees93 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price81.17
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-64.07% Payout- Rel Volume0.60 Prev Close42.91
Sales Surprise- EPS Surprise19.35% Sales Q/Q- EarningsMar 08 BMO Avg Volume632.69K Price42.86
SMA2010.05% SMA502.49% SMA200-0.88% Trades Volume380,258 Change-0.12%
Date Action Analyst Rating Change Price Target Change
Oct-19-23Initiated JMP Securities Mkt Outperform $90
Jul-27-23Initiated Piper Sandler Overweight $58
May-25-23Resumed Jefferies Buy $34 → $41
Feb-28-23Initiated SVB Securities Outperform $33
Feb-28-23Initiated Jefferies Buy $34
Feb-28-23Initiated Guggenheim Buy $50
Feb-28-23Initiated BMO Capital Markets Outperform $40
Mar-15-24 10:53AM
Mar-08-24 04:05PM
08:30AM
Jan-22-24 05:24AM
Dec-25-23 07:45AM
04:21PM Loading…
Dec-22-23 04:21PM
Dec-18-23 04:06PM
01:03PM
11:29AM
09:22AM
07:30AM
07:30AM
06:23AM
Dec-11-23 12:26PM
Nov-29-23 02:28PM
02:30AM Loading…
02:30AM
Nov-27-23 09:50AM
Nov-26-23 04:44PM
Nov-14-23 04:10PM
Nov-03-23 05:20AM
Oct-19-23 08:45AM
Oct-06-23 08:45AM
Oct-02-23 03:48PM
Sep-29-23 04:04PM
12:50PM
11:19AM
10:24AM
09:34AM
07:32AM
07:30AM
04:05PM Loading…
Aug-10-23 04:05PM
Aug-03-23 05:32PM
Jul-16-23 07:00AM
Jun-27-23 02:10PM
01:35PM
08:12AM
Jun-26-23 09:05PM
Jun-16-23 08:00AM
Jun-13-23 06:10AM
Jun-12-23 10:15AM
Jun-07-23 08:30AM
May-31-23 04:30PM
May-25-23 04:30PM
May-18-23 04:30PM
May-11-23 04:30PM
May-03-23 06:59AM
Mar-30-23 04:30PM
Feb-07-23 04:00PM
Feb-06-23 03:17PM
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in South San Francisco, CA.